Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SIGA Technologies gets FDA nod for TPOXX to treat smallpox
TPOXX is claimed to be the first drug with an indication for treatment of smallpox, which is a contagious and fatal infectious disease. The approval of small-molecule antiviral
TPOXX is claimed to be the first drug with an indication for treatment of smallpox, which is a contagious and fatal infectious disease. The approval of small-molecule antiviral
The partnership will engage in the discovery and development of next-generation bispecific immunotherapies for multiple cancer indications. Under the deal, Immatics will secure an upfront fee of $54m
Visterra is engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Otsuka Pharmaceutical representative director and president
Idera said that majority of its stockholders voted in favor of the adoption of the merger agreement with BioCryst. BioCryst will pay $6m as transaction-related expenses to Idera,
As per the cash-cum stock deal signed in early May, the Japanese pharma company offers to pay $30.33 in cash for each Shire share in addition to either
The agency said that the recall pertains to medicines which use valsartan supplied by China-based Zhejiang Huahai Pharmaceuticals. It revealed that the review was launched after Zhejiang Huahai
Lojuxta has received approval for funding as an NHS treatment for adult patients with Homozygous Familial Hypercholesterolaemia (HoFH) in England. The first in class medicine can reduce the
Apart from the approval of the UK marketing authorisation application, Alliance Pharma has also received the agency’s nod to market the prescription nausea drug under the brand name
The companies have also announced research collaboration for the development of five additional gene therapy products in neurological disorders. Benitec’s silence-and-replace gene therapy technology has been designed to deliver a
The Pennsylvania-based cannabinoid-based drug developer reported that the drug, which is delivered via a transdermal patch, could not achieve the target blood levels of 5 to 15ng/ml THC